MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Neisseria Meningitidis
Interventions
BIOLOGICAL

Trumenba

"Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains two lipidated factor H binding protein (fHbp) variants-A05 from subfamily A and B01 from subfamily B-delivered in a 0.5 mL prefilled syringe. Each dose includes 120 µg of protein (60 µg per variant), 0.018 mg polysorbate 80, and 0.25 mg aluminum as AlPO₄, formulated in histidine-buffered saline at pH 6.0.~A single intramuscular dose will be administered in the deltoid."

BIOLOGICAL

PENBRAYA

"PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. It consists of two components:~* A lyophilized MenACWY portion (polysaccharides conjugated to tetanus toxoid)~* A liquid MenB portion (two recombinant fHbp variants: A05 and B01) Each 0.5 mL dose contains 20 µg of polysaccharides (5 µg per serogroup), 44 µg tetanus toxoid, 120 µg of MenB protein (60 µg per variant), plus stabilizers and aluminum phosphate.~This will be administered intramuscularly in the deltoid."

Trial Locations (2)

30329

Emory Children's Center-Vaccine Research Clinic, Atlanta

Hope Clinic, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Emory University

OTHER